Piper Sandler Reiterates Neutral on Hims & Hers Health, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Korinne Wolfmeyer has reiterated a Neutral rating on Hims & Hers Health (NYSE:HIMS) and maintained the price target at $18.
August 06, 2024 | 5:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler analyst Korinne Wolfmeyer has reiterated a Neutral rating on Hims & Hers Health (NYSE:HIMS) and maintained the price target at $18.
The reiteration of a Neutral rating and maintenance of the $18 price target suggests that the analyst does not foresee significant short-term changes in the stock's performance. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100